GABA Therapeutics, Inc
GABA Therapeutics is a midstage biotechnology company focused on developing novel therapies for psychiatric and neurological disorders. They are working on a deuterated version of etifoxine, called GRX-917, which aims to provide faster, lower-dose, and more stable treatment options for anxiety and related conditions. Their approach leverages deuteration technology to improve existing drugs, potentially increasing success rates and reducing side effects. The company has secured funding, is conducting clinical trials in Australia, and plans to move towards IPO within the next two years.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Clinical‑stage deuterated anxiolytic candidate
A deuterated analog of an established anxiolytic designed to improve metabolic stability and pharmacokinetics while preserving a mechanism that increases endogenous neurosteroids and modulates inhibitory neurotransmission.
Clinical‑stage deuterated anxiolytic candidate
A deuterated analog of an established anxiolytic designed to improve metabolic stability and pharmacokinetics while preserving a mechanism that increases endogenous neurosteroids and modulates inhibitory neurotransmission.
Services
Form co‑development alliances and strategic partnerships to advance clinical‑stage CNS compounds through early clinical milestones and to provide funding and development expertise.
Form co‑development alliances and strategic partnerships to advance clinical‑stage CNS compounds through early clinical milestones and to provide funding and development expertise.
Expertise Areas
- Clinical trial management
- Neurosteroid pharmacology
- Deuteration medicinal chemistry
- qEEG biomarker development
Key Technologies
- Deuterium substitution (deuteration) chemistry
- Quantitative EEG (qEEG)
- TSPO modulation assays
- Neurosteroid quantification assays
News & Updates
GABA Therapeutics Commences Phase I Study in Etifoxine – Melbourne Australia
GABA Therapeutics has started dosing in its Phase I clinical trial of etifoxine in Melbourne, Australia, evaluating pharmacokinetics, pharmacodynamics, and safety in healthy volunteers.
GABA Therapeutics Completes Single Ascending Dose (SAD) Stage of Phase 1 Study in GRX-917 in Melbourne
The company successfully completed the SAD stage of its Phase 1 study, with favorable safety results up to 500mg.
GABA Therapeutics Appoints Mario David Saltarelli M.D., Ph.D. as CEO and CMO
The company announced the appointment of Mario David Saltarelli as CEO and CMO.
GABA Therapeutics Completed Phase 1 Etifoxine in Melbourne
GABA Therapeutics completed its Phase 1 clinical trial of etifoxine in Melbourne, Australia.
GABA Therapeutics receives approval to begin Phase I clinical trials
The company received approval to conduct a Phase I trial of etifoxine in Melbourne, Australia.
Precision qEEG Biomarker Demonstrates Anxiolytic Efficacy in Phase 1 GRX-917 and Phase 1 Etifoxine
Biomarkers demonstrated anxiolytic efficacy in Phase 1 trials of GRX-917 and etifoxine.
GABA Therapeutics Commences Phase I Study in Etifoxine – Melbourne Australia
GABA Therapeutics has started dosing in its Phase I clinical trial of etifoxine in Melbourne, Australia, evaluating pharmacokinetics, pharmacodynamics, and safety in healthy volunteers.
GABA Therapeutics Completes Single Ascending Dose (SAD) Stage of Phase 1 Study in GRX-917 in Melbourne
The company successfully completed the SAD stage of its Phase 1 study, with favorable safety results up to 500mg.
GABA Therapeutics Appoints Mario David Saltarelli M.D., Ph.D. as CEO and CMO
The company announced the appointment of Mario David Saltarelli as CEO and CMO.
GABA Therapeutics Completed Phase 1 Etifoxine in Melbourne
GABA Therapeutics completed its Phase 1 clinical trial of etifoxine in Melbourne, Australia.
GABA Therapeutics receives approval to begin Phase I clinical trials
The company received approval to conduct a Phase I trial of etifoxine in Melbourne, Australia.
Precision qEEG Biomarker Demonstrates Anxiolytic Efficacy in Phase 1 GRX-917 and Phase 1 Etifoxine
Biomarkers demonstrated anxiolytic efficacy in Phase 1 trials of GRX-917 and etifoxine.